AIM: To investigate the possible correlation of nucleophosmin/B23 expression with bladder carcinoma recurrence. METHODS: Surgically-resected bladder tumors staged pTa to pT4 were examined for nucleophosmin/B23 expression by immuno-histochemistry. The study group consisted of 132 consecutive patients surgically treated at Chang Gung Memorial Hospital between December 1998 and November 1999. The mean follow up was 72 months (range: 48-84 months). RESULTS: Nuclear nucleophosmin/B23 staining was detected in 96% of advanced stage and poorly-differentiated tumors. Higher nucleophosmin/B23 levels were linked to more advanced tumor stages, grades, poor prognosis, and likelihood of recurrence (P<0.05). The Cox multivariate analysis indicated the nucleophosmin/B23 expression as an independent indicator for tumor recurrence (P=0.009). CONCLUSION: The results suggest that nucleophosmin/B23 is a favorable prognostic indicator for bladder cancer. Nucleophosmin/B23 could be a useful molecular tumor marker for predicting bladder cancer recurrence.
AIM: To investigate the possible correlation of nucleophosmin/B23 expression with bladder carcinoma recurrence. METHODS: Surgically-resected bladder tumors staged pTa to pT4 were examined for nucleophosmin/B23 expression by immuno-histochemistry. The study group consisted of 132 consecutive patients surgically treated at Chang Gung Memorial Hospital between December 1998 and November 1999. The mean follow up was 72 months (range: 48-84 months). RESULTS: Nuclear nucleophosmin/B23 staining was detected in 96% of advanced stage and poorly-differentiated tumors. Higher nucleophosmin/B23 levels were linked to more advanced tumor stages, grades, poor prognosis, and likelihood of recurrence (P<0.05). The Cox multivariate analysis indicated the nucleophosmin/B23 expression as an independent indicator for tumor recurrence (P=0.009). CONCLUSION: The results suggest that nucleophosmin/B23 is a favorable prognostic indicator for bladder cancer. Nucleophosmin/B23 could be a useful molecular tumor marker for predicting bladder cancer recurrence.
Authors: Zhi-qiang Wang; Jun Zhao; Jin Zeng; Kai-jie Wu; Yu-le Chen; Xin-yang Wang; Luke S Chang; Da-lin He Journal: Acta Pharmacol Sin Date: 2011-10-24 Impact factor: 6.150
Authors: Piia-Riitta Karhemo; Antti Rivinoja; Johan Lundin; Maija Hyvönen; Anastasiya Chernenko; Johanna Lammi; Harri Sihto; Mikael Lundin; Päivi Heikkilä; Heikki Joensuu; Petri Bono; Pirjo Laakkonen Journal: Am J Pathol Date: 2011-06-02 Impact factor: 4.307
Authors: Angel C Y Yu; Yi-Jye Chern; Peter Zhang; Clarissa C Pasiliao; Mahbuba Rahman; George Chang; Jianhua Ren; Isabella T Tai Journal: Cancer Biol Ther Date: 2021-01-15 Impact factor: 4.742
Authors: L Lam; Z Aktary; M Bishay; C Werkman; C-Y Kuo; M Heacock; N Srivastava; J R Mackey; M Pasdar Journal: Oncogenesis Date: 2012-03-19 Impact factor: 7.485